[Comparison of the therapeutic effect of the Warfarin and Rivaroksaban among the patients with not-valuate fibrillation of atrium].

In this article the results of comparative assessment of the efficiency of the Rivaroksaban and Varfarine for prevention of stroke and systemic embolic complications in middle and high- stroke risk patients with nonvalvular artial fibrillation are presented. Detailed analysis of some risk factors is conducted according to scales: CHADS2, CHA2DS2-VASc and HAS-BLED. The frequency of development of endpoints is defined (stroke, TIA, system embolism, cardiac infarction or death due to cardiovascular reasons, or combination of outcomes) according to initial risk and anticoagulant treatment. Connection between "retention" of INR and the risk of the thromboembolic and hemorrhagic complications in patients treated with Varfarine are analyzed.